The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth
factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular …

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

Fumarate hydratase (FH) mutation causes hereditary type 2 papillary renal cell carcinoma (PRCC2).
The main effect of FH mutation is fumarate accumulation. The current paradigm …

To better understand the molecular mechanisms that underlie the tumorigenesis and progression
of clear cell renal cell carcinoma (ccRCC), we studied the gene expression profiles of …

We report clinicopathologic features of a large series of renal translocation carcinomas from
a multicentric study. Diagnosis was performed by cytogenetic examination of fresh material …

Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a
disproportionately limited understanding of its underlying genetic programs. There is no effective …

Tumor hypoxia is associated with disease progression, resistance to conventional cancer
therapies and poor prognosis 1 , 2 . Hypoxia, by largely unknown mechanisms, leads to …

Although the functions of most of the identified microRNAs (miRNAs) have yet to be determined,
their use as potential biomarkers has been considered in several human diseases and …

Papillary renal cell carcinoma (RCC) represents 10% to 15% of adult renal neoplasms;
however, the molecular genetic events that are associated with the development and …

Sustained activation of the stress-regulated transcription factor NRF2 (NFE2L2) is a prominent
feature of many types of cancer, implying that mutations driving NRF2 may be important to …